{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T18:03:52Z","timestamp":1764785032961,"version":"3.37.3"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s11033-022-08180-9","type":"journal-article","created":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T13:05:11Z","timestamp":1671455111000},"page":"2685-2700","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immunotherapeutics in lung cancers: from mechanistic insight to clinical implications and synergistic perspectives"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1155-0094","authenticated-orcid":false,"given":"Hardeep Singh","family":"Tuli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek K.","family":"Garg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renuka","family":"Choudhary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashif","family":"Iqubal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin","family":"Sak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adesh K.","family":"Saini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reena V.","family":"Saini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanupriya","family":"Vashishth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuldeep","family":"Dhama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranjan K.","family":"Mohapatra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhruv Sanjay","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ginpreet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,19]]},"reference":[{"key":"8180_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"8180_CR2","volume-title":"Intrinsic and extrinsic pathways of apoptosis: role in cancer development and prognosis","author":"D Kashyap","year":"2021","unstructured":"Kashyap D, Garg VK, Goel N (2021) Intrinsic and extrinsic pathways of apoptosis: role in cancer development and prognosis, 1 edn, vol 125. Elsevier Inc., Amsterdam","edition":"1"},{"key":"8180_CR3","first-page":"256","volume":"3","author":"D Kashyap","year":"2016","unstructured":"Kashyap D, Sharma A, Garg V, Tuli HS, Kumar G, Kumar M (2016) Reactive Oxygen Species (ROS ): an activator of apoptosis and autophagy in cancer. J Biol Chem Sci 3:256\u2013264","journal-title":"J Biol Chem Sci"},{"key":"8180_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.31031\/nacs.2018.01.000520","volume":"1","author":"VK Garg","year":"2018","unstructured":"Garg VK, Kashyap D, Tuli HS (2018) Targeting telomerase and topoisomerase-II by natural moieties: an anti-cancer approach. Approaches Cancer Stud 1:3\u20134. https:\/\/doi.org\/10.31031\/nacs.2018.01.000520","journal-title":"Approaches Cancer Stud"},{"key":"8180_CR5","doi-asserted-by":"publisher","first-page":"656","DOI":"10.3390\/ijms20030656","volume":"20","author":"V Aggarwal","year":"2019","unstructured":"Aggarwal V, Kashyap D, Sak K, Tuli HS, Jain A, Chaudhary A, Garg VK, Sethi G, Yerer MB (2019) Molecular mechanisms of action of tocotrienols in cancer: Recent trends and advancements. Int J Mol Sci 20:656. https:\/\/doi.org\/10.3390\/ijms20030656","journal-title":"Int J Mol Sci"},{"key":"8180_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biom9050174","volume":"9","author":"D Kashyap","year":"2019","unstructured":"Kashyap D, Garg VK, Tuli HS, Yerer MB, Sak K, Sharma AK, Kumar M, Aggarwal V, Sandhu SS (2019) Fisetin and quercetin: promising flavonoids with chemopreventive potential. Biomolecules 9:1\u201322. https:\/\/doi.org\/10.3390\/biom9050174","journal-title":"Biomolecules"},{"key":"8180_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.semcancer.2019.08.014","volume":"69","author":"D Kashyap","year":"2021","unstructured":"Kashyap D, Tuli HS, Yerer MB, Sharma A, Sak K, Srivastava S, Pandey A, Garg VK, Sethi G, Bishayee A (2021) Natural product-based nanoformulations for cancer therapy: opportunities and challenges. Semin Cancer Biol 69:5\u201323. https:\/\/doi.org\/10.1016\/j.semcancer.2019.08.014","journal-title":"Semin Cancer Biol"},{"key":"8180_CR8","doi-asserted-by":"publisher","first-page":"423","DOI":"10.37349\/etat.2022.00092","volume":"3","author":"K Sak","year":"2022","unstructured":"Sak K (2022) Anticancer action of plant products: changing stereotyped attitudes. Explor Target Antitumor Ther 3:423\u2013427. https:\/\/doi.org\/10.37349\/etat.2022.00092","journal-title":"Explor Target Antitumor Ther"},{"key":"8180_CR9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s40291-018-0316-1","volume":"22","author":"D Kashyap","year":"2018","unstructured":"Kashyap D, Tuli HS, Garg VK, Goel N, Bishayee A (2018) Oncogenic and tumor-suppressive roles of micrornas with special reference to apoptosis: molecular mechanisms and therapeutic potential. Mol Diagnosis Ther 22:179\u2013201","journal-title":"Mol Diagnosis Ther"},{"key":"8180_CR10","doi-asserted-by":"publisher","first-page":"9735","DOI":"10.2147\/CMAR.S272277","volume":"12","author":"L Lu","year":"2020","unstructured":"Lu L, Liang Q, Shen S, Feng L, Jin L, Liang ZF (2020) Tobacco smoke plays an important role in initiation and development of lung cancer by promoting the characteristics of cancer stem cells. Cancer Manag Res 12:9735\u20139739. https:\/\/doi.org\/10.2147\/CMAR.S272277","journal-title":"Cancer Manag Res"},{"key":"8180_CR11","doi-asserted-by":"publisher","first-page":"CD011751","DOI":"10.1002\/14651858.cd011751.pub3","volume":"6","author":"L Zeng","year":"2019","unstructured":"Zeng L, Yu X, Yu T, Xiao J, Huang Y (2019) Interventions for smoking cessation in people diagnosed with lung cancer. Cochrane Database Syst Rev 6:CD011751. https:\/\/doi.org\/10.1002\/14651858.cd011751.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"8180_CR12","doi-asserted-by":"publisher","first-page":"01","DOI":"10.13188\/2330-2178.1000042","volume":"6","author":"V Garg","year":"2018","unstructured":"Garg V, Kashyap D (2018) Smoking habit among youngsters. J Addict Prev 6:01\u201301. https:\/\/doi.org\/10.13188\/2330-2178.1000042","journal-title":"J Addict Prev"},{"key":"8180_CR13","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3892\/OL.2016.5518","volume":"13","author":"M Kanwal","year":"2017","unstructured":"Kanwal M, Ding XJ, Cao Y (2017) Familial risk for lung cancer. Oncol Lett 13:535\u2013542. https:\/\/doi.org\/10.3892\/OL.2016.5518","journal-title":"Oncol Lett"},{"key":"8180_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/J.JENVRAD.2018.05.017","volume":"192","author":"N Vogeltanz-Holm","year":"2018","unstructured":"Vogeltanz-Holm N, Schwartz GG (2018) Radon and lung cancer: what does the public really know? J Environ Radioact 192:26\u201331. https:\/\/doi.org\/10.1016\/J.JENVRAD.2018.05.017","journal-title":"J Environ Radioact"},{"key":"8180_CR15","doi-asserted-by":"publisher","first-page":"200288","DOI":"10.1183\/16000617.0288-2020","volume":"30","author":"S Lam","year":"2021","unstructured":"Lam S, Tammemagi M (2021) Contemporary issues in the implementation of lung cancer screening. Eur Respir Rev 30:200288. https:\/\/doi.org\/10.1183\/16000617.0288-2020","journal-title":"Eur Respir Rev"},{"key":"8180_CR16","doi-asserted-by":"publisher","first-page":"100791","DOI":"10.1016\/J.CURRPROBLCANCER.2021.100791","volume":"46","author":"T Xue","year":"2022","unstructured":"Xue T, Zhao X, Zhao K, Lu Y, Yao J, Ji X (2022) Immunotherapy for lung cancer: focusing on chimeric antigen receptor (CAR)-T cell therapy. Curr Probl Cancer 46:100791. https:\/\/doi.org\/10.1016\/J.CURRPROBLCANCER.2021.100791","journal-title":"Curr Probl Cancer"},{"key":"8180_CR17","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1097\/CM9.0000000000001082","volume":"133","author":"HH Zhu","year":"2020","unstructured":"Zhu HH, Feng Y, Hu XS (2020) Emerging immunotherapy targets in lung cancer. Chin Med J 133:2456\u20132465. https:\/\/doi.org\/10.1097\/CM9.0000000000001082","journal-title":"Chin Med J"},{"key":"8180_CR18","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.21037\/tlcr-20-827","volume":"9","author":"WY Xia","year":"2020","unstructured":"Xia WY, Feng W, Zhang CC, Shen YJ, Zhang Q, Yu W, Cai XW, Fu XL (2020) Radiotherapy for non-small cell lung cancer in the immunotherapy era: the opportunity and challenge-a narrative review. Transl Lung Cancer Res 9:2120\u20132136. https:\/\/doi.org\/10.21037\/tlcr-20-827","journal-title":"Transl Lung Cancer Res"},{"key":"8180_CR19","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1097\/PPO.0000000000000485","volume":"26","author":"L Sun","year":"2020","unstructured":"Sun L, Aggarwal C (2020) Immunotherapy for lung cancer-improving outcomes in patients with locally advanced non-small cell lung cancer with immunotherapy. Cancer J 26:548\u2013554. https:\/\/doi.org\/10.1097\/PPO.0000000000000485","journal-title":"Cancer J"},{"key":"8180_CR20","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1002\/ijc.25516","volume":"127","author":"J Ferlay","year":"2010","unstructured":"Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893\u20132917. https:\/\/doi.org\/10.1002\/ijc.25516","journal-title":"Int J Cancer"},{"key":"8180_CR21","doi-asserted-by":"publisher","first-page":"288","DOI":"10.21037\/tlcr.2016.06.07","volume":"5","author":"C Zappa","year":"2016","unstructured":"Zappa C, Mousa SA (2016) Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res 5:288\u2013300. https:\/\/doi.org\/10.21037\/tlcr.2016.06.07","journal-title":"Transl Lung Cancer Res"},{"key":"8180_CR22","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/JNCI\/91.14.1194","volume":"91","author":"SS Hecht","year":"1999","unstructured":"Hecht SS (1999) Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 91:1194\u20131210. https:\/\/doi.org\/10.1093\/JNCI\/91.14.1194","journal-title":"J Natl Cancer Inst"},{"key":"8180_CR23","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jama.287.9.1132","volume":"287","author":"CA Pope","year":"2002","unstructured":"Pope CA, Burnett RT, Thun MJ, Calle EE, Krewski D, Ito K, Thurston GD (2002) Lung cancer, cardiopulmonary mortality, and long-term exposure to fine particulate air pollution. J Am Med Assoc 287:1132\u20131141. https:\/\/doi.org\/10.1001\/jama.287.9.1132","journal-title":"J Am Med Assoc"},{"key":"8180_CR24","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/PPO.0B013E318233E6B4","volume":"17","author":"RJ Kelly","year":"2011","unstructured":"Kelly RJ, Giaccone G (2011) Lung cancer vaccines. Cancer J 17:302\u2013308. https:\/\/doi.org\/10.1097\/PPO.0B013E318233E6B4","journal-title":"Cancer J"},{"key":"8180_CR25","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/NRI1150","volume":"3","author":"OJ Finn","year":"2003","unstructured":"Finn OJ (2003) Cancer vaccines: between the idea and the reality. Nat Rev Immunol 3:630\u2013641. https:\/\/doi.org\/10.1038\/NRI1150","journal-title":"Nat Rev Immunol"},{"key":"8180_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.PHARMTHERA.2015.05.004","volume":"153","author":"M Freeman-Keller","year":"2015","unstructured":"Freeman-Keller M, Goldman J, Gray J (2015) Vaccine immunotherapy in lung cancer: clinical experience and future directions. Pharmacol Ther 153:1\u20139. https:\/\/doi.org\/10.1016\/J.PHARMTHERA.2015.05.004","journal-title":"Pharmacol Ther"},{"key":"8180_CR27","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1093\/annonc\/mdg102","volume":"14","author":"G Gonzalez","year":"2003","unstructured":"Gonzalez G, Crombet T, Torres F, Catala M, Alfonso L, Osorio M, Neninger E, Garcia B, Mulet A, Perez R et al (2003) Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy. Ann Oncol 14:461\u2013466. https:\/\/doi.org\/10.1093\/annonc\/mdg102","journal-title":"Ann Oncol"},{"key":"8180_CR28","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S1470-2045(13)70510-2","volume":"15","author":"C Butts","year":"2014","unstructured":"Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosqu\u00e9e L, Trigo JM et al (2014) Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 15:59\u201368. https:\/\/doi.org\/10.1016\/S1470-2045(13)70510-2","journal-title":"Lancet Oncol"},{"key":"8180_CR29","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/S1470-2045(16)00099-1","volume":"17","author":"JF Vansteenkiste","year":"2016","unstructured":"Vansteenkiste JF, Cho BC, Vanakesa T, De Pas T, Zielinski M, Kim MS, Jassem J, Yoshimura M, Dahabreh J, Nakayama H et al (2016) Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 17:822\u2013835. https:\/\/doi.org\/10.1016\/S1470-2045(16)00099-1","journal-title":"Lancet Oncol"},{"key":"8180_CR30","doi-asserted-by":"publisher","first-page":"280ps7","DOI":"10.1126\/SCITRANSLMED.AAA3643","volume":"7","author":"CH June","year":"2015","unstructured":"June CH, Riddell SR, Schumacher TN (2015) Adoptive cellular therapy: a race to the finish line. Sci Transl Med 7:280ps7. https:\/\/doi.org\/10.1126\/SCITRANSLMED.AAA3643","journal-title":"Sci Transl Med"},{"key":"8180_CR31","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s00262-018-2174-4","volume":"67","author":"R Ben-Avi","year":"2018","unstructured":"Ben-Avi R, Farhi R, Ben-Nun A, Gorodner M, Greenberg E, Markel G, Schachter J, Itzhaki O, Besser MJ (2018) Establishment of adoptive cell therapy with tumor infiltrating lymphocytes for non-small cell lung cancer patients. Cancer Immunol Immunother 67:1221\u20131230. https:\/\/doi.org\/10.1007\/s00262-018-2174-4","journal-title":"Cancer Immunol Immunother"},{"key":"8180_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-018-0404-5","volume":"9","author":"D Chen","year":"2018","unstructured":"Chen D, Sha H, Hu T, Dong S, Zhang J, Liu S, Cao H, Ma R, Wu Y, Jing C et al (2018) Cytokine-induced killer cells as a feasible adoptive immunotherapy for the treatment of lung cancer article. Cell Death Dis 9:1\u201312. https:\/\/doi.org\/10.1038\/s41419-018-0404-5","journal-title":"Cell Death Dis"},{"key":"8180_CR33","doi-asserted-by":"publisher","first-page":"800","DOI":"10.3389\/FIMMU.2018.00800","volume":"9","author":"T Hoeres","year":"2018","unstructured":"Hoeres T, Smetak M, Pretscher D, Wilhelm M (2018) Improving the efficiency of V\u03b39V\u03b42 T-cell immunotherapy in cancer. Front Immunol 9:800. https:\/\/doi.org\/10.3389\/FIMMU.2018.00800","journal-title":"Front Immunol"},{"key":"8180_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/FIMMU.2018.02021","volume":"2018","author":"M Takami","year":"2021","unstructured":"Takami M, Ihara F, Motohashi S (2021) Clinical application of iNKT cell-mediated anti-tumor activity against lung cancer and head and neck cancer. Front Immunol 2018:9. https:\/\/doi.org\/10.3389\/FIMMU.2018.02021","journal-title":"Front Immunol"},{"key":"8180_CR35","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","volume":"27","author":"BC Creelan","year":"2021","unstructured":"Creelan BC, Wang C, Teer JK, Toloza EM, Yao J, Kim S, Landin AM, Mullinax JE, Saller JJ, Saltos AN et al (2021) Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat Med 27:1410\u20131418. https:\/\/doi.org\/10.1038\/s41591-021-01462-y","journal-title":"Nat Med"},{"key":"8180_CR36","doi-asserted-by":"publisher","first-page":"4556","DOI":"10.3389\/FIMMU.2021.782775","volume":"12","author":"BF Xiao","year":"2021","unstructured":"Xiao BF, Zhang JT, Zhu YG, Cui XR, Lu ZM, Yu BT, Wu N (2021) Chimeric antigen receptor T-cell therapy in lung cancer: potential and challenges. Front Immunol 12:4556. https:\/\/doi.org\/10.3389\/FIMMU.2021.782775","journal-title":"Front Immunol"},{"key":"8180_CR37","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce JA, Fearon DT (2015) T cell exclusion, immune privilege, and the tumor microenvironment. Science 348:74\u201380. https:\/\/doi.org\/10.1126\/science.aaa6204","journal-title":"Science"},{"key":"8180_CR38","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC et al (2018) Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 24:541\u2013550. https:\/\/doi.org\/10.1038\/s41591-018-0014-x","journal-title":"Nat Med"},{"key":"8180_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13045-017-0458-3","volume":"10","author":"T Achkar","year":"2017","unstructured":"Achkar T, Tarhini AA (2017) The use of immunotherapy in the treatment of melanoma. J Hematol Oncol 10:1\u20139. https:\/\/doi.org\/10.1186\/S13045-017-0458-3","journal-title":"J Hematol Oncol"},{"key":"8180_CR40","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1634\/theoncologist.2009-0028","volume":"14","author":"C Robert","year":"2009","unstructured":"Robert C, Ghiringhelli F (2009) What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma? Oncologist 14:848\u2013861. https:\/\/doi.org\/10.1634\/theoncologist.2009-0028","journal-title":"Oncologist"},{"key":"8180_CR41","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC et al (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:1027\u20131034. https:\/\/doi.org\/10.1084\/jem.192.7.1027","journal-title":"J Exp Med"},{"issue":"7","key":"8180_CR42","doi-asserted-by":"publisher","first-page":"2326s","DOI":"10.1158\/1078-0432.CCR-05-2517","volume":"12","author":"TF Gajewski","year":"2006","unstructured":"Gajewski TF (2006) Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment. Clin Cancer Res 12(7):2326s\u20132330s. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-2517","journal-title":"Clin Cancer Res"},{"key":"8180_CR43","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","volume":"99","author":"Y Iwai","year":"2002","unstructured":"Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99:12293\u201312297. https:\/\/doi.org\/10.1073\/pnas.192461099","journal-title":"Proc Natl Acad Sci USA"},{"key":"8180_CR44","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/85330","volume":"2","author":"Y Latchman","year":"2001","unstructured":"Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R et al (2001) PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2:261\u2013268. https:\/\/doi.org\/10.1038\/85330","journal-title":"Nat Immunol"},{"key":"8180_CR45","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3978\/J.ISSN.2218-6751.2015.06.05","volume":"4","author":"DR Carrizosa","year":"2015","unstructured":"Carrizosa DR, Gold KA (2015) New strategies in immunotherapy for non-small cell lung cancer. Transl lung cancer Res 4:553\u2013559. https:\/\/doi.org\/10.3978\/J.ISSN.2218-6751.2015.06.05","journal-title":"Transl lung cancer Res"},{"key":"8180_CR46","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1080\/21645515.2016.1249551","volume":"13","author":"APS Silva","year":"2017","unstructured":"Silva APS, Coelho PV, Anazetti M, Simioni PU (2017) Targeted therapies for the treatment of non-small-cell lung cancer: monoclonal antibodies and biological inhibitors. Hum Vaccin Immunother 13:843\u2013853. https:\/\/doi.org\/10.1080\/21645515.2016.1249551","journal-title":"Hum Vaccin Immunother"},{"key":"8180_CR47","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1634\/theoncologist.2008-0290","volume":"15","author":"G Pueyo","year":"2010","unstructured":"Pueyo G, Mesia R, Figueras A, Lozano A, Baro M, Vazquez S, Capella G, Balart J (2010) Cetuximab may inhibit tumor growth and angiogenesis induced by ionizing radiation: a preclinical rationale for maintenance treatment after radiotherapy. Oncologist 15:976\u2013986. https:\/\/doi.org\/10.1634\/theoncologist.2008-0290","journal-title":"Oncologist"},{"key":"8180_CR48","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.lungcan.2012.03.010","volume":"77","author":"R Pirker","year":"2012","unstructured":"Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Eberhardt WEE, de Marinis F et al (2012) Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study. Lung Cancer 77:376\u2013382. https:\/\/doi.org\/10.1016\/j.lungcan.2012.03.010","journal-title":"Lung Cancer"},{"key":"8180_CR49","doi-asserted-by":"publisher","first-page":"e81897","DOI":"10.1371\/journal.pone.0081897","volume":"8","author":"X Li","year":"2013","unstructured":"Li X, Shan BE, Wang J, Xing LP, Guo XJ, Zhang YH, Shi PH, Wang ZY (2013) Incidence and risk of treatment-related mortality with anti-epidermal growth factor receptor monoclonal antibody in cancer patients: a meta-analysis of 21 randomized controlled trials. PLoS ONE 8:e81897. https:\/\/doi.org\/10.1371\/journal.pone.0081897","journal-title":"PLoS ONE"},{"key":"8180_CR50","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1200\/JCO.2009.21.9618","volume":"28","author":"TJ Lynch","year":"2010","unstructured":"Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC, Paschold E, Iannotti NO, Dakhil S, Gorton S et al (2010) Cetuximab and first-line taxane\/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 28:911\u2013917. https:\/\/doi.org\/10.1200\/JCO.2009.21.9618","journal-title":"J Clin Oncol"},{"key":"8180_CR51","doi-asserted-by":"publisher","first-page":"165","DOI":"10.4161\/MABS.2.2.11360","volume":"2","author":"LA Sullivan","year":"2010","unstructured":"Sullivan LA, Brekken RA (2010) The VEGF family in cancer and antibody-based strategies for their inhibition. MAbs 2:165\u2013175. https:\/\/doi.org\/10.4161\/MABS.2.2.11360","journal-title":"MAbs"},{"key":"8180_CR52","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/NRC925","volume":"2","author":"S Rafii","year":"2002","unstructured":"Rafii S, Lyden D, Benezra R, Hattori K, Heissig B (2002) Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2:826\u2013835. https:\/\/doi.org\/10.1038\/NRC925","journal-title":"Nat Rev Cancer"},{"key":"8180_CR53","first-page":"307","volume":"36","author":"T Kubota","year":"2016","unstructured":"Kubota T, Okano Y, Sakai M, Takaoka M, Tsukuda T, Anabuki K, Kawase S, Miyamoto S, Ohnishi H, Hatakeyama N et al (2016) Carboplatin plus weekly paclitaxel with bevacizumab for first-line treatment of non-small cell lung cancer. Anticancer Res 36:307\u2013312","journal-title":"Anticancer Res"},{"key":"8180_CR54","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/jcph.191","volume":"54","author":"L Claret","year":"2014","unstructured":"Claret L, Gupta M, Han K, Joshi A, Sarapa N, He J, Powell B, Bruno R (2014) Prediction of overall survival or progression free survival by disease control rate at week 8 is independent of ethnicity: western versus Chinese patients with first-line non-small cell lung cancer treated with chemotherapy with or without bevacizumab. J Clin Pharmacol 54:253\u2013257. https:\/\/doi.org\/10.1002\/jcph.191","journal-title":"J Clin Pharmacol"},{"key":"8180_CR55","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/labinvest.2015.60","volume":"95","author":"H Saijo","year":"2015","unstructured":"Saijo H, Tatsumi N, Arihiro S, Kato T, Okabe M, Tajiri H, Hashimoto H (2015) Microangiopathy triggers, and inducible nitric oxide synthase exacerbates dextran sulfate sodium-induced colitis. Lab Investig 95:728\u2013748. https:\/\/doi.org\/10.1038\/labinvest.2015.60","journal-title":"Lab Investig"},{"key":"8180_CR56","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1200\/JCO.2005.02.477","volume":"23","author":"RS Herbst","year":"2005","unstructured":"Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G, Lee JJ, Liu DD, Truong MT et al (2005) Phase I\/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1\/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung canc. J Clin Oncol 23:2544\u20132555. https:\/\/doi.org\/10.1200\/JCO.2005.02.477","journal-title":"J Clin Oncol"},{"key":"8180_CR57","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677\u2013704. https:\/\/doi.org\/10.1146\/annurev.immunol.26.021607.090331","journal-title":"Annu Rev Immunol"},{"key":"8180_CR58","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2217\/FON-2015-0012","volume":"12","author":"M Reck","year":"2016","unstructured":"Reck M, Heigener D, Reinmuth N (2016) Immunotherapy for small-cell lung cancer: emerging evidence. Future Oncol 12:931\u2013943. https:\/\/doi.org\/10.2217\/FON-2015-0012","journal-title":"Future Oncol"},{"key":"8180_CR59","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1634\/theoncologist.2015-0498","volume":"21","author":"J Sul","year":"2016","unstructured":"Sul J, Blumenthal GM, Jiang X, He K, Keegan P, Pazdur R (2016) FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1. Oncologist 21:643\u2013650. https:\/\/doi.org\/10.1634\/theoncologist.2015-0498","journal-title":"Oncologist"},{"key":"8180_CR60","doi-asserted-by":"publisher","first-page":"202","DOI":"10.21037\/TLCR.2018.09.15","volume":"8","author":"S Rashdan","year":"2019","unstructured":"Rashdan S, Gerber DE (2019) Immunotherapy for non-small cell lung cancer: from clinical trials to real-world practice. Transl Lung Cancer Res 8:202\u2013207. https:\/\/doi.org\/10.21037\/TLCR.2018.09.15","journal-title":"Transl Lung Cancer Res"},{"key":"8180_CR61","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, Felip E, P\u00e9rez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540\u20131550. https:\/\/doi.org\/10.1016\/S0140-6736(15)01281-7","journal-title":"Lancet"},{"key":"8180_CR62","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/nejmoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, Gottfried M, Peled N, Tafreshi A, Cuffe S et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823\u20131833. https:\/\/doi.org\/10.1056\/nejmoa1606774","journal-title":"N Engl J Med"},{"key":"8180_CR63","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","volume":"387","author":"L Fehrenbacher","year":"2016","unstructured":"Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C et al (2016) Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387:1837\u20131846. https:\/\/doi.org\/10.1016\/S0140-6736(16)00587-0","journal-title":"Lancet"},{"key":"8180_CR64","doi-asserted-by":"publisher","first-page":"S251","DOI":"10.1016\/j.jtho.2016.09.009","volume":"11","author":"H Wakelee","year":"2016","unstructured":"Wakelee H, Patel JD, Heist R, Balmanoukian A, Besse B, Felip E, Carcereny Costa E, Chow LQ, Koczywas M, Garassino MC et al (2016) ORAL01.04: phase II trial of atezolizumab for patients with PD-L1-selected advanced NSCLC (BIRCH): updated efficacy and exploratory biomarker results. J Thorac Oncol 11:S251\u2013S252. https:\/\/doi.org\/10.1016\/j.jtho.2016.09.009","journal-title":"J Thorac Oncol"},{"key":"8180_CR65","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1056\/nejmc1716426","volume":"378","author":"SJ Antonia","year":"2018","unstructured":"Antonia SJ, \u00d6zg\u00fcro\u011flu M (2018) Durvalumab in stage III non-small-cell lung cancer. N Engl J Med 378:868\u2013870. https:\/\/doi.org\/10.1056\/nejmc1716426","journal-title":"N Engl J Med"},{"key":"8180_CR66","unstructured":"Search of: resveratrol | Phase 4\u2014List Results\u2014ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/ct2\/results?term=immunotherapy&cond=Lung+Cancer&age_v=&gndr=&type=&rslt=&phase=3&Search=Apply. Accessed 4 Apr 2022"},{"key":"8180_CR67","doi-asserted-by":"publisher","first-page":"180037","DOI":"10.1098\/RSOB.180037","volume":"8","author":"J Van den Bulk","year":"2018","unstructured":"Van den Bulk J, Verdegaal EME, De Miranda NFCC (2018) Cancer immunotherapy: broadening the scope of targetable tumours. Open Biol 8:180037. https:\/\/doi.org\/10.1098\/RSOB.180037","journal-title":"Open Biol"},{"issue":"1","key":"8180_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13045-019-0736-3","volume":"12","author":"S Yang","year":"2019","unstructured":"Yang S, Zhang Z, Wang Q (2019) Emerging therapies for small cell lung cancer. J Hematol Oncol 12(1):1\u201311. https:\/\/doi.org\/10.1186\/S13045-019-0736-3","journal-title":"J Hematol Oncol"},{"key":"8180_CR69","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1007\/S00262-020-02752-Z","volume":"70","author":"EM Brozos-V\u00e1zquez","year":"2021","unstructured":"Brozos-V\u00e1zquez EM, D\u00edaz-Pe\u00f1a R, Garc\u00eda-Gonz\u00e1lez J, Le\u00f3n-Mateos L, Mondelo-Mac\u00eda P, Pe\u00f1a-Chilet M, L\u00f3pez-L\u00f3pez R (2021) Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy. Cancer Immunol Immunother 70:1177\u20131188. https:\/\/doi.org\/10.1007\/S00262-020-02752-Z","journal-title":"Cancer Immunol Immunother"},{"key":"8180_CR70","doi-asserted-by":"publisher","first-page":"595","DOI":"10.2174\/1568009619666181210114559","volume":"19","author":"T Nagano","year":"2018","unstructured":"Nagano T, Tachihara M, Nishimura Y (2018) Molecular mechanisms and targeted therapies including immunotherapy for non-small cell lung cancer. Curr Cancer Drug Targets 19:595\u2013630. https:\/\/doi.org\/10.2174\/1568009619666181210114559","journal-title":"Curr Cancer Drug Targets"},{"key":"8180_CR71","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/CAC2.12153","volume":"41","author":"J Kang","year":"2021","unstructured":"Kang J, Zhang C, Zhong WZ (2021) Neoadjuvant immunotherapy for non-small cell lung cancer: state of the art. Cancer Commun 41:287\u2013302. https:\/\/doi.org\/10.1002\/CAC2.12153","journal-title":"Cancer Commun"},{"key":"8180_CR72","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.thorsurg.2020.01.006","volume":"30","author":"J Judd","year":"2020","unstructured":"Judd J, Borghaei H (2020) Combining immunotherapy and chemotherapy for non-small cell lung cancer. Thorac Surg Clin 30:199\u2013206. https:\/\/doi.org\/10.1016\/j.thorsurg.2020.01.006","journal-title":"Thorac Surg Clin"},{"issue":"1","key":"8180_CR73","doi-asserted-by":"publisher","first-page":"1996686","DOI":"10.1080\/2162402X.2021.1996686","volume":"10","author":"G Kroemer","year":"2021","unstructured":"Kroemer G, Kepp O (2021) Small cell lung cancer responds to immunogenic chemotherapy followed by PD-1 blockade. Oncoimmunology 10(1):1996686. https:\/\/doi.org\/10.1080\/2162402X.2021.1996686","journal-title":"Oncoimmunology"},{"key":"8180_CR74","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/CCO.0000000000000700","volume":"33","author":"R Pirker","year":"2021","unstructured":"Pirker R (2021) Immunotherapy combinations in advanced nonsmall cell lung cancer. Curr Opin Oncol 33:73\u201379. https:\/\/doi.org\/10.1097\/CCO.0000000000000700","journal-title":"Curr Opin Oncol"},{"key":"8180_CR75","doi-asserted-by":"publisher","first-page":"5792","DOI":"10.1158\/1078-0432.CCR-17-3620","volume":"24","author":"EC Ko","year":"2018","unstructured":"Ko EC, Raben D, Formenti SC (2018) The integration of radiotherapy with immunotherapy for the treatment of non\u2013small cell lung cancer. Clin Cancer Res 24:5792\u20135806. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-3620","journal-title":"Clin Cancer Res"},{"key":"8180_CR76","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/7652014","author":"C Carbone","year":"2019","unstructured":"Carbone C, Piro G, Di Noia V, D\u2019Argento E, Vita E, Ferrara MG, Pilotto S, Milella M, Cammarota G, Gasbarrini A et al (2019) Lung and gut microbiota as potential hidden driver of immunotherapy efficacy in lung cancer. Mediators Inflamm. https:\/\/doi.org\/10.1155\/2019\/7652014","journal-title":"Mediators Inflamm"},{"issue":"5","key":"8180_CR77","doi-asserted-by":"publisher","first-page":"100273","DOI":"10.1016\/j.esmoop.2021.100273","volume":"6","author":"M Reck","year":"2021","unstructured":"Reck M, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O et al (2021) First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update. ESMO Open 6(5):100273. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100273","journal-title":"ESMO Open"},{"key":"8180_CR78","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","volume":"9","author":"WSME Theelen","year":"2021","unstructured":"Theelen WSME, Chen D, Verma V, Hobbs BP, Peulen HMU, Aerts JGJV, Bahce I, Niemeijer ALN, Chang JY, de Groot PM et al (2021) Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med 9:467\u2013475. https:\/\/doi.org\/10.1016\/S2213-2600(20)30391-X","journal-title":"Lancet Respir Med"},{"issue":"22","key":"8180_CR79","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1200\/JCO.19.03158","volume":"38","author":"M Reck","year":"2020","unstructured":"Reck M, Wehler T, Orlandi F, Nogami N, Barone C, Moro-Sibilot D, Shtivelband M, Larriba JLG, Rothenstein J, Fr\u00fch M et al (2020) Safety and patient-reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab versus bevacizumab plus chemotherapy in non-small-cell lung cancer. J Clin Oncol 38(22):2530\u20132542","journal-title":"J Clin Oncol"},{"key":"8180_CR80","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2020.0409","volume":"6","author":"O Arrieta","year":"2020","unstructured":"Arrieta O, Barr\u00f3n F, Ram\u00edrez-Tirado LA, Zatarain-Barr\u00f3n ZL, Cardona AF, D\u00edaz-Garc\u00eda D, Yamamoto Ramos M, Mota-Vega B, Carmona A, Peralta \u00c1lvarez MP et al (2020) Efficacy and safety of pembrolizumab plus docetaxel vs docetaxel alone in patients with previously treated advanced non-small cell lung cancer: the PROLUNG phase 2 randomized clinical trial. JAMA Oncol 6:856\u2013864. https:\/\/doi.org\/10.1001\/jamaoncol.2020.0409","journal-title":"JAMA Oncol"},{"key":"8180_CR81","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, \u00d6zg\u00fcro\u011flu M, Ji JH et al (2019) Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394:1929\u20131939. https:\/\/doi.org\/10.1016\/S0140-6736(19)32222-6","journal-title":"Lancet"},{"key":"8180_CR82","doi-asserted-by":"publisher","first-page":"5787","DOI":"10.1158\/1078-0432.CCR-19-0070","volume":"25","author":"R Hassan","year":"2019","unstructured":"Hassan R, Alley E, Kindler H, Antonia S, Jahan T, Honarmand S, Nair N, Whiting CC, Enstrom A, Lemmens E et al (2019) Clinical response of live-attenuated, listeria monocytogenes expressing mesothelin (CRS-207) with chemotherapy in patients with malignant pleural mesothelioma. Clin Cancer Res 25:5787\u20135798. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0070","journal-title":"Clin Cancer Res"},{"key":"8180_CR83","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/J.JTHO.2020.05.019","volume":"15","author":"LM Sholl","year":"2020","unstructured":"Sholl LM, Hirsch FR, Hwang D, Botling J, Lopez-Rios F, Bubendorf L, Mino-Kenudson M, Roden AC, Beasley MB, Borczuk A et al (2020) The promises and challenges of tumor mutation burden as an immunotherapy biomarker: a perspective from the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol 15:1409\u20131424. https:\/\/doi.org\/10.1016\/J.JTHO.2020.05.019","journal-title":"J Thorac Oncol"},{"key":"8180_CR84","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1158\/1078-0432.CCR-14-1187","volume":"21","author":"VK Anagnostou","year":"2015","unstructured":"Anagnostou VK, Brahmer JR (2015) Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer. Clin Cancer Res 21:976\u2013984. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-1187","journal-title":"Clin Cancer Res"},{"key":"8180_CR85","doi-asserted-by":"publisher","first-page":"106613","DOI":"10.1016\/J.INTIMP.2020.106613","volume":"85","author":"Z Wu","year":"2020","unstructured":"Wu Z, Man S, Sun R, Li Z, Wu Y, Zuo D (2020) Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer. Int Immunopharmacol 85:106613. https:\/\/doi.org\/10.1016\/J.INTIMP.2020.106613","journal-title":"Int Immunopharmacol"},{"key":"8180_CR86","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.rmcr.2017.07.004","volume":"22","author":"P Zarogoulidis","year":"2017","unstructured":"Zarogoulidis P, Chinelis P, Athanasiadou A, Tsiouda T, Trakada G, Kallianos A, Veletza L, Hatzibougias D, Mihalopoulou E, Goupou E et al (2017) Possible adverse effects of immunotherapy in non-small cell lung cancer; treatment and follow-up of three cases. Respir Med Case Rep 22:101\u2013105. https:\/\/doi.org\/10.1016\/j.rmcr.2017.07.004","journal-title":"Respir Med Case Rep"},{"key":"8180_CR87","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/978-3-030-02505-2_3","volume":"995","author":"L Corrales","year":"2018","unstructured":"Corrales L, Scilla K, Caglevic C, Miller K, Oliveira J, Rolfo C (2018) Immunotherapy in lung cancer: a new age in cancer treatment. Adv Exp Med Biol 995:65\u201395","journal-title":"Adv Exp Med Biol"},{"key":"8180_CR88","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1111\/RESP.12789","volume":"21","author":"A Steven","year":"2016","unstructured":"Steven A, Fisher SA, Robinson BW (2016) Immunotherapy for lung cancer. Respirology 21:821\u2013833. https:\/\/doi.org\/10.1111\/RESP.12789","journal-title":"Respirology"},{"issue":"1","key":"8180_CR89","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3390\/CANCERS14010122","volume":"14","author":"RAB De Mello","year":"2021","unstructured":"De Mello RAB, Voscaboinik R, Luciano JVP, Cremonese RV, Amaral GA, Castelo-Branco P, Antoniou G (2021) Immunotherapy in patients with advanced non-small cell lung cancer lacking driver mutations and future perspectives. Cancers 14(1):122. https:\/\/doi.org\/10.3390\/CANCERS14010122","journal-title":"Cancers"},{"key":"8180_CR90","doi-asserted-by":"publisher","first-page":"115","DOI":"10.21147\/j.issn.1000-9604.2020.01.13","volume":"32","author":"H Guo","year":"2020","unstructured":"Guo H, Li L, Cui J (2020) Advances and challenges in immunotherapy of small cell lung cancer. Chin J Cancer Res 32:115\u2013128. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2020.01.13","journal-title":"Chin J Cancer Res"},{"key":"8180_CR91","doi-asserted-by":"publisher","first-page":"v917","DOI":"10.1093\/annonc\/mdz394.078","volume":"30","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Langer CJ, Novello S, Halmos B, Cheng Y, Gadgeel SM, Hui R, Sugawara S, Borghaei H, Cristescu R et al (2019) Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407. Ann Oncol 30:v917\u2013v918. https:\/\/doi.org\/10.1093\/annonc\/mdz394.078","journal-title":"Ann Oncol"},{"key":"8180_CR92","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1159\/000510385","volume":"99","author":"L Gaissmaier","year":"2020","unstructured":"Gaissmaier L, Christopoulos P (2020) Immune modulation in lung cancer: current concepts and future strategies. Respiration 99:903\u2013929. https:\/\/doi.org\/10.1159\/000510385","journal-title":"Respiration"},{"key":"8180_CR93","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1080\/14737140.2019.1631800","volume":"19","author":"D Rocco","year":"2019","unstructured":"Rocco D, Della Gravara L, Battiloro C, Gridelli C (2019) The role of combination chemo-immunotherapy in advanced non-small cell lung cancer. Expert Rev Anticancer Ther 19:561\u2013568. https:\/\/doi.org\/10.1080\/14737140.2019.1631800","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"8180_CR94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13045-017-0456-5","volume":"10","author":"A Somasundaram","year":"2017","unstructured":"Somasundaram A, Burns TF (2017) The next generation of immunotherapy: keeping lung cancer in check. J Hematol Oncol 10(1):1\u201312. https:\/\/doi.org\/10.1186\/S13045-017-0456-5","journal-title":"J Hematol Oncol"},{"key":"8180_CR95","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.21037\/JTD.2018.01.79","volume":"10","author":"JS Kurman","year":"2018","unstructured":"Kurman JS, Murgu SD (2018) Hyperprogressive disease in patients with non-small cell lung cancer on immunotherapy. J Thorac Dis 10:1124\u20131128. https:\/\/doi.org\/10.21037\/JTD.2018.01.79","journal-title":"J Thorac Dis"},{"key":"8180_CR96","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1001\/jamaoncol.2020.1634","volume":"6","author":"B Kas","year":"2020","unstructured":"Kas B, Talbot H, Ferrara R, Richard C, Lamarque JP, Pitre-Champagnat S, Planchard D, Balleyguier C, Besse B, Mezquita L et al (2020) Clarification of definitions of hyperprogressive disease during immunotherapy for non-small cell lung cancer. JAMA Oncol 6:1039\u20131046. https:\/\/doi.org\/10.1001\/jamaoncol.2020.1634","journal-title":"JAMA Oncol"},{"key":"8180_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/CANCERS12123729","volume":"12","author":"L Boyero","year":"2020","unstructured":"Boyero L, S\u00e1nchez-Gastaldo A, Alonso M, Noguera-Ucl\u00e9s JF, Molina-Pinelo S, Bernab\u00e9-Caro R (2020) Primary and acquired resistance to immunotherapy in lung cancer: unveiling the mechanisms underlying of immune checkpoint blockade therapy. Cancers 12:1\u201336. https:\/\/doi.org\/10.3390\/CANCERS12123729","journal-title":"Cancers"},{"key":"8180_CR98","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1080\/14712598.2019.1592155","volume":"19","author":"G Hamilton","year":"2019","unstructured":"Hamilton G, Rath B (2019) Immunotherapy for small cell lung cancer: mechanisms of resistance. Expert Opin Biol Ther 19:423\u2013432. https:\/\/doi.org\/10.1080\/14712598.2019.1592155","journal-title":"Expert Opin Biol Ther"},{"key":"8180_CR99","doi-asserted-by":"publisher","first-page":"100889","DOI":"10.1016\/J.TRANON.2020.100889","volume":"14","author":"W Huang","year":"2021","unstructured":"Huang W, Chen JJ, Xing R, Zeng YC (2021) Combination therapy: Future directions of immunotherapy in small cell lung cancer. Transl Oncol 14:100889. https:\/\/doi.org\/10.1016\/J.TRANON.2020.100889","journal-title":"Transl Oncol"},{"key":"8180_CR100","doi-asserted-by":"publisher","first-page":"603157","DOI":"10.3389\/FIMMU.2020.603157","volume":"11","author":"S Li","year":"2020","unstructured":"Li S, Zhang C, Pang G, Wang P (2020) Emerging blood-based biomarkers for predicting response to checkpoint immunotherapy in non-small-cell lung cancer. Front Immunol 11:603157. https:\/\/doi.org\/10.3389\/FIMMU.2020.603157","journal-title":"Front Immunol"},{"key":"8180_CR101","doi-asserted-by":"publisher","first-page":"65","DOI":"10.4155\/fdd-2021-0006","volume":"3","author":"CB Ray","year":"2021","unstructured":"Ray CB, Vijayarasa V, Vankad M, Sherif M, Harky A (2021) The role of immunotherapy in treating lung cancer: current status and future perspective. Future Drug Discov 3:65. https:\/\/doi.org\/10.4155\/fdd-2021-0006","journal-title":"Future Drug Discov"},{"key":"8180_CR102","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/pcmedi\/pbab027","volume":"4","author":"W Luo","year":"2021","unstructured":"Luo W, Wang Z, Zhang T, Yang L, Xian J, Li Y, Li W (2021) Immunotherapy in non-small cell lung cancer: rationale, recent advances and future perspectives. Precis Clin Med 4:258\u2013270. https:\/\/doi.org\/10.1093\/pcmedi\/pbab027","journal-title":"Precis Clin Med"},{"key":"8180_CR103","doi-asserted-by":"publisher","first-page":"378","DOI":"10.4110\/IN.2017.17.6.378","volume":"17","author":"JH Cho","year":"2017","unstructured":"Cho JH (2017) Immunotherapy for non-small-cell lung cancer: current status and future obstacles. Immune Netw 17:378\u2013391. https:\/\/doi.org\/10.4110\/IN.2017.17.6.378","journal-title":"Immune Netw"},{"issue":"10","key":"8180_CR104","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.3390\/LIFE11101029","volume":"11","author":"T Kinoshita","year":"2021","unstructured":"Kinoshita T, Terai H, Yaguchi T (2021) Clinical efficacy and future prospects of immunotherapy in lung cancer. Life 11(10):1029. https:\/\/doi.org\/10.3390\/LIFE11101029","journal-title":"Life"},{"issue":"1","key":"8180_CR105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-017-0274-x","volume":"5","author":"C Tosch","year":"2017","unstructured":"Tosch C, Bastien B, Barraud L, Grellier B, Nourtier V, Gantzer M, Limacher JM, Quemeneur E, Bendjama K, Pr\u00e9ville X (2017) Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC. J Immunother Cancer 5(1):1\u201310. https:\/\/doi.org\/10.1186\/s40425-017-0274-x","journal-title":"J Immunother Cancer"},{"key":"8180_CR106","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1080\/14712598.2018.1492539","volume":"18","author":"M Tagliamento","year":"2018","unstructured":"Tagliamento M, Rijavec E, Barletta G, Biello F, Rossi G, Grossi F, Genova C (2018) CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine. Expert Opin Biol Ther 18:829\u2013835. https:\/\/doi.org\/10.1080\/14712598.2018.1492539","journal-title":"Expert Opin Biol Ther"},{"key":"8180_CR107","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3390\/medicines5040114","volume":"5","author":"P Lamichhane","year":"2018","unstructured":"Lamichhane P, Amin N, Agarwal M, Lamichhane N (2018) Checkpoint inhibition: will combination with radiotherapy and nanoparticle-mediated delivery improve efficacy? Medicines 5:114. https:\/\/doi.org\/10.3390\/medicines5040114","journal-title":"Medicines"},{"key":"8180_CR108","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ejca.2018.06.033","volume":"101","author":"SV Liu","year":"2018","unstructured":"Liu SV, Camidge DR, Gettinger SN, Giaccone G, Heist RS, Hodi FS, Ready NE, Zhang W, Wallin J, Funke R et al (2018) Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non\u2013small-cell lung cancer. Eur J Cancer 101:114\u2013122. https:\/\/doi.org\/10.1016\/j.ejca.2018.06.033","journal-title":"Eur J Cancer"},{"key":"8180_CR109","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/S40261-018-00746-5","volume":"39","author":"L Long","year":"2019","unstructured":"Long L, Zhao C, Ozarina M, Zhao X, Yang J, Chen H (2019) Targeting immune checkpoints in lung cancer: current landscape and future prospects. Clin Drug Investig 39:341\u2013353. https:\/\/doi.org\/10.1007\/S40261-018-00746-5","journal-title":"Clin Drug Investig"},{"key":"8180_CR110","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/S12254-018-0411-3","volume":"11","author":"LA Mauti","year":"2018","unstructured":"Mauti LA, Finazzi T, Fr\u00fch M, Pless M, Zippelius A, Rothschild SI (2018) Current and future developments of immunotherapy in lung cancer. Memo-Mag Eur Med Oncol 11:122\u2013131. https:\/\/doi.org\/10.1007\/S12254-018-0411-3","journal-title":"Memo-Mag Eur Med Oncol"},{"key":"8180_CR111","doi-asserted-by":"publisher","first-page":"7707","DOI":"10.2147\/CMAR.S212238","volume":"11","author":"H Liang","year":"2019","unstructured":"Liang H, Wang M (2019) Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer. Cancer Manag Res 11:7707\u20137719. https:\/\/doi.org\/10.2147\/CMAR.S212238","journal-title":"Cancer Manag Res"},{"key":"8180_CR112","doi-asserted-by":"publisher","DOI":"10.1136\/JITC-2021-002531","author":"F Li","year":"2021","unstructured":"Li F, Deng L, Jackson KR, Talukder AH, Katailiha AS, Bradley SD, Zou Q, Chen C, Huo C, Chiu Y et al (2021) Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. J Immunother Cancer. https:\/\/doi.org\/10.1136\/JITC-2021-002531","journal-title":"J Immunother Cancer"},{"key":"8180_CR113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18053\/jctres.07.202101.001","volume":"20","author":"X Mielgo-Rubio","year":"2021","unstructured":"Mielgo-Rubio X, Uribelarrea EA, Cort\u00e9s LQ, Moyano MS (2021) Immunotherapy in non-small cell lung cancer: update and new insights. J Clin Transl Res 20:1\u201321. https:\/\/doi.org\/10.18053\/jctres.07.202101.001","journal-title":"J Clin Transl Res"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-022-08180-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-022-08180-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-022-08180-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T22:38:13Z","timestamp":1679870293000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-022-08180-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,19]]},"references-count":113,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["8180"],"URL":"https:\/\/doi.org\/10.1007\/s11033-022-08180-9","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"type":"print","value":"0301-4851"},{"type":"electronic","value":"1573-4978"}],"subject":[],"published":{"date-parts":[[2022,12,19]]},"assertion":[{"value":"4 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declared there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This is a review paper. Therefore, no ethical approval is required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}